An update from Neuren Pharmaceuticals Limited ( ($AU:NEU) ) is now available. Neuren Pharmaceuticals announced the receipt of its one-third share ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company with a market capitalization of $3.06 billion, focuses on developing and commercializing innovative medicines to address unmet ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Legend Biotech Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

It's not easy to deal with tragedy, but for Colin Endres and the D-Y/CCT/CCA boys hockey team, they're honoring his sister ...

Taysha Gene Therapies offers hope for Rett syndrome with innovative treatment, strong trial results, and promising regulatory ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

Rett syndrome is a rare neurological and developmental disorder that leads to a gradual decline in motor skills and language. An X-linked genetic disease, Rett syndrome occurs in approximately 1 in ...

In March 2023, the US Food and Drug Administration approved Acadia's Daybue (trofinetide) for treating Rett syndrome in adults and paediatric patients aged two years and above. The therapy is also ...

The news: Neuren Pharmaceuticals' Rett syndrome treatment, trofinetide, is a step closer to receiving regulatory approval in the European Union, after its US partner Acadia Pharmaceuticals submitted a ...